-continued

<220> FEATURE:
<223> OTHER INFORMATION: DNA primer

<400> SEQUENCE: 571

tcgttggcct gattctcccc 20

<210> SEQ ID NO 572
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: DNA primer

<400> SEQUENCE: 572

gccagaggtt tttgctcagg 20

<210> SEQ ID NO 573
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: DNA primer

<400> SEQUENCE: 573

caggacaacg ttcacacgg 19

1. A plurality of isogenic mammalian cells, wherein one or more endogenous glycogenes have been inactivated and/or wherein one or more exogenous glycogene have been introduced independently in individual cells of said plurality of mammalian cells.

2.-**14**. (canceled)

15. The plurality of isogenic mammalian cells of claim **1**, furthermore encoding an exogenous protein of interest or induced to overexpress an endogenous protein of interest.

16.-**18**. (canceled)

19. The plurality of isogenic mammalian cells of claim **15**, in which the protein of interest is a lysosomal enzyme expressed to comprise one or more posttranslational modifications independently selected from:

a) with α2,3NeuAc capping,

b) without α2,3NeuAc capping,

c) with α2,6NeuAc capping,

d) without α2,6NeuAc capping,

e) without LacDiNac structure,

f) high Mannose6phosphate,

g) low Mannose6phosphate,

h) without bisecting glycoforms; and

i) with high mannose.

20. The plurality of isogenic mammalian cells of claim **1**, wherein said one or more endogenous glycogene inactivated and/or exogenous glycogene introduced independently in individual cells of said plurality of mammalian cells is selected from the list of GNPTAB, GNPTG, NAGPA, ALG3/6/8/9/10/12s, Mannosidases (MAN1A1, MAN1A2, MAN1B1, MAN1C1, MAN2A1, MAN2A2), MOGS, GANAB plus MGAT1/2 and Sialyl transferases.

21. The plurality of isogenic mammalian cells of claim **1** wherein said one or more endogenous glycogene inactivated is GNPTAB, such as in order to increase sialic acids.

22. The plurality of isogenic mammalian cells of claim **19**, wherein said lysosomal enzyme has obtained increased mannose-6-phosphate (M6P) tagging of N-glycans and/or has obtained changed site occupancy of M6P, such as by knocking out a gene selected from ALG3, ALG8, NAGPA.

23. The plurality of isogenic mammalian cells of claim **19**, wherein said lysosomal enzyme has obtained increased high mannose structures, such as by knocking out a gene selected from MGAT1 and/or GNPTAB and/or MOGS.

24.-**39**. (canceled)

40. The plurality of isogenic mammalian cells of claim **1**, wherein one or more of said cells has an inactivation and/or introduction of one or more glycogene selected from the list consisting of glycogenes associated with subset of O-Mannose type glycoproteins (listed in Table 5 under group 1 genes for O-Glycans), such as POMT1 and/or POMT2 and/or TMTC1 and/or TMTC2 and/or TMTC3 and/or TMTC4 (Group 1).

41.-**43**. (canceled)

44. The plurality of isogenic mammalian cells of claim **1**, wherein one or more of said cells has an inactivation and/or introduction of one or more glycogene selected from the list consisting of MGAT1 (N-Glycans), COSMC (O-GalNac), B4GALT7 (Glycosaminoglycans, GAG), B4GALT5/6 (Glycosphingolipids), POMGNT1 (O-Man) (Group 2).

45. (canceled)

46. The plurality of isogenic mammalian cells of claim **1**, wherein one or more of said cells has an inactivation and/or introduction of one or more glycogene selected from the list consisting of MGAT2/3/4A/4B/4C/4D/5/5B, MAN1A1, MAN1A2, MAN1B1, MAN1C1, MAN2A1, MAN2A2, MOGS, GANAB, B3GALT1/T2/T4/T5, B3GALNT1/T2, B3GNT2/T3/T4/T6/T7/T8/T9, B4GALT1/T2/T3/T4, B4GALNT1/T2/T3/T4, GCNT1/T2/T3/T4/T6/T7, B3GAT1/T2, B4GAT1, LARGE, GYLT1B (LARGE2),